MedPath

Pyridoxine

Generic Name
Pyridoxine
Brand Names
Alertonic, Animi-3 With Vitamin D, Bonjesta, Citranatal B-calm Kit, Citranatal Harmony, Concept Ob, Diclectin, Diclegis, Folbic, Foltabs, Fortaplex, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Isotamine B, Mvc-fluoride, Mvi Pediatric, Natafort, Neo-bex, Pregvit, Tandem Plus, Vitafol-one
Drug Type
Small Molecule
Chemical Formula
C8H11NO3
CAS Number
65-23-6
Unique Ingredient Identifier
KV2JZ1BI6Z
Background

Pyridoxine is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods. As its classification as a vitamin implies, Vitamin B6 (and pyridoxine) are essential nutrients required for normal functioning of many biological systems within the body. While many plants and microorganisms are able to synthesize pyridoxine through endogenous biological processes, animals must obtain it through their diet.

More specifically, pyridoxine is converted to pyridoxal 5-phosphate in the body, which is an important coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, and aminolevulinic acid. It's important to note that Vitamin B6 is the collective term for a group of three related compounds, pyridoxine, pyridoxal, and pyridoxamine, and their phosphorylated derivatives, pyridoxine 5'-phosphate, pyridoxal 5'-phosphate and pyridoxamine 5'-phosphate. Although all six of these compounds should technically be referred to as vitamin B6, the term vitamin B6 is commonly used interchangeably with just one of them, pyridoxine .

Vitamin B6, principally in its biologically active coenzyme form pyridoxal 5'-phosphate, is involved in a wide range of biochemical reactions, including the metabolism of amino acids and glycogen, the synthesis of nucleic acids, hemogloblin, sphingomyelin and other sphingolipids, and the synthesis of the neurotransmitters serotonin, dopamine, norepinephrine and gamma-aminobutyric acid (GABA) .

Pyridoxine is used medically for the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy (due to Isoniazid's mechanism of action which competitively inhibits the action of pyridoxine in the above-mentioned metabolic functions). It is also used in combination with Doxylamine (as the commercially available product Diclectin) for the treatment of nausea and vomiting in pregnancy.

Indication

Pyridoxine is indicated for the treatment of vitamin B6 deficiency and for the prophylaxis of Isoniazid-induced peripheral neuropathy. It is also approved by Health Canada for the treatment of nausea and vomiting in pregnancy in a combination product with Doxylamine (as the commercially available product Diclectin).

Associated Conditions
Back pain, Dizziness, Fever, Headache, Hepatic; Functional Disturbance, Hepatitis, Iron Deficiency Anemia (IDA), Ketosis, Macrocytic anemia, Menière's Disease, Menstrual Distress (Dysmenorrhea), Metabolic Acidosis, Motion Sickness, Myalgia, Nausea and vomiting, Neuralgia, Sciatic, Neuritis, Neurological Conditions caused by B Vitamin Deficiency, Secondary anemia, Toothache, Toxinfectious state, Trigeminal Neuralgia (TN), Vitamin B1 deficiency, Vitamin B12 Deficiency, Vitamin B6 Deficiency, Vitamin Deficiency, Minor aches and pains, Minor pain
Associated Therapies
Nutritional supplementation, Supplementation, Vitamin supplementation, Wellness of the Liver

Genetic Variants Linked to Vincristine-Induced Peripheral Neuropathy Identified

• Researchers have identified novel genomic variations associated with both increased risk and protection against vincristine-induced peripheral neuropathy (VIPN). • The study highlights the role of genes involved in neuronal development and axonal transport in VIPN susceptibility, offering potential therapeutic targets. • These findings could lead to personalized approaches in chemotherapy to minimize neurotoxic side effects in acute lymphoblastic leukemia (ALL) treatment. • Further research is needed to validate these findings and explore clinical applications for risk prediction and targeted interventions.

Genomic Medicine Evolution: Bridging the Gap Between Promise and Clinical Reality

• Genomic medicine is advancing beyond initial human genome project expectations, with scientists now focusing on understanding the crucial 98% of non-protein-coding regions that regulate gene expression. • Long-read sequencing technology is emerging as a breakthrough tool for understanding complex genetic disorders, offering more comprehensive insights than traditional short-read methods. • Gene therapy using adeno-associated virus (AAV) vectors has achieved clinical success, notably in treating spinal muscular atrophy, marking a significant step toward personalized genomic medicine.
© Copyright 2025. All Rights Reserved by MedPath